UBS Group AG - TSCAN THERAPEUTICS INC ownership

TSCAN THERAPEUTICS INC's ticker is and the CUSIP is 89854M101. A total of 25 filers reported holding TSCAN THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of TSCAN THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,854
+3.8%
1,115
+1.4%
0.00%
Q2 2023$2,750
-59.6%
1,100
-66.0%
0.00%
Q1 2023$6,804
+339.0%
3,240
+224.0%
0.00%
Q4 2022$1,550
-85.9%
1,000
-70.9%
0.00%
Q3 2022$11,000
+175.0%
3,441
+199.7%
0.00%
Q2 2022$4,0000.0%1,148
+41.6%
0.00%
Q4 2021$4,000
-50.0%
811
-14.3%
0.00%
Q3 2021$8,0009460.00%
Other shareholders
TSCAN THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
DC Funds, LP 630,000$1,612,80033.20%
Lynx1 Capital Management LP 5,224,600$13,374,9768.85%
EcoR1 Capital, LLC 5,000,000$12,800,0000.43%
Deer Management Co. LLC 1,245,505$3,188,4930.39%
Simplify Asset Management Inc. 1,046,916$2,680,1050.31%
BVF INC/IL 2,989,474$7,653,0530.21%
Alphabet Inc. 1,077,080$2,757,3240.18%
DC Investments Management, LLC 35,563$91,0410.11%
Baker Brothers Advisors 2,784,792$7,129,0680.04%
Privium Fund Management (UK) Ltd 15,825$41,4620.03%
View complete list of TSCAN THERAPEUTICS INC shareholders